Search clinical trials for: Lilly

Total 2754 results

Eli Lilly and Company
Boehringer Ingelheim

Completed

To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence

Stress Urinary Incontinence

United States
Eli Lilly and Company

Completed

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

Attention-Deficit/Hyperactivity Disorder

United States
Eli Lilly and Company

Completed

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

Turner Syndrome

United States
Eli Lilly and Company

Completed

Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents

Attention Deficit Hyperactivity Disorder

Sweden
Association of Urologic Oncology (AUO)
Eli Lilly and Company

Unknown

Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer

Carcinoma, Transitional Cell | Bladder Cancer

Germany
Eli Lilly and Company

Terminated

Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

Ovarian Cancer | Peritoneal Cancer

United States
Hamilton Health Sciences Corporation
Eli Lilly and Company

Completed

Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

Trichotillomania

Canada
Eli Lilly and Company

Completed

Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

Carcinoma, Transitional Cell

United States
Eli Lilly and Company

Completed

Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Canada
Eli Lilly and Company

Completed

Local Registration Trial in China Humalog Mix 50

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

China
Eli Lilly and Company
Boehringer Ingelheim

Completed

Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions.

Stress Urinary Incontinence

United States
Eli Lilly and Company

Completed

Duloxetine in the Treatment of Melancholic Depression

Depressive Disorder, Major

Australia, Canada
Eli Lilly and Company

Completed

Switching to Duloxetine From Other Antidepressants

Major Depressive Disorder

Spain, France, Ireland, United Kingdom
Eli Lilly and Company

Completed

Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode

Bipolar Disorder

Spain
Eli Lilly and Company

Completed

Olanzapine in Patients With Borderline Personality Disorder

Borderline Personality Disorder

Germany, United States, Belgium, France, Norway, Portugal, Spain, Sweden, United Kingdom
Eli Lilly and Company

Completed

A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity

United States
Eli Lilly and Company

Completed

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

Borderline Personality Disorder

United States, Argentina, Poland, Romania, Turkey
Eli Lilly and Company

Completed

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

Major Depressive Disorder

United States, Canada
Eli Lilly and Company

Completed

Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Carcinoma, Non-Small-Cell Lung

Russian Federation
Eli Lilly and Company

Completed

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Schizophrenia

United States
Eli Lilly and Company

Completed

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

Sepsis

United States, Canada, Brazil, Mexico, Australia, Czech Republic, Slovakia, Spain, Austria, Belgium, Chile, Denmark, Egypt, Finland, France, Germany, India, Italy, Lebanon, Netherlands, New Zealand, Norway, Romania, Russian Federation, Saudi... and more
Eli Lilly and Company

Completed

ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.

Lung Neoplasms

United States
Eli Lilly and Company

Completed

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

Osteoporosis, Postmenopausal

United States
Eli Lilly and Company

Completed

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Alzheimer's Disease

United States
Eli Lilly and Company

Completed

A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Urologic Neoplasms

Finland, France, Germany
Eli Lilly and Company

Completed

ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

Cancer | Metastases

United States
Eli Lilly and Company

Completed

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

Depression | Schizophrenia | Schizoaffective Disorder

United States
Eli Lilly and Company

Completed

Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain

Depression | Pain

United States
Eli Lilly and Company

Completed

A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis

Sepsis

United States, Poland, Belgium, Netherlands, Hungary
Eli Lilly and Company

Completed

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Pancreatic Neoplasms | Metastases, Neoplasm

United States, France, United Kingdom, Germany, Taiwan, Spain, Belgium, Portugal, Peru, Austria, Italy, Sweden, Netherlands, Venezuela, Argentina, Australia, Colombia, Greece
Eli Lilly and Company

Completed

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

Carcinoma, Non-Small-Cell Lung | Neoplasms, Lung | Pulmonary Neoplasms

United States
Eli Lilly and Company

Completed

ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

Carcinoma, Non-Small-Cell Lung

United States
Eli Lilly and Company

Completed

EVA: Evista Alendronate Comparison

Osteoporosis

United States, Canada
Eli Lilly and Company

Completed

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Urologic Neoplasms | Metastases, Neoplasm

United States
Eli Lilly and Company

Completed

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, France, Germany, Taiwan, Spain, Belgium, Switzerland, Netherlands, Russian Federation, South Africa, Poland, Hungary, Italy, Norway, India, Sweden, Argentina, United Kingdom, Puerto Rico, Chile, Romania
Eli Lilly and Company

Completed

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Schizophrenia

United States, United Kingdom, Spain, Argentina, Mexico, Brazil, Peru, Puerto Rico, Germany, Austria, Ireland, Venezuela
Eli Lilly and Company

Completed

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Psychotic Disorders | Schizophrenia | Bipolar Disorder

United States
Eli Lilly and Company

Completed

Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

Argentina, Belgium, Brazil, Mexico, Portugal
Eli Lilly and Company

Completed

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
Eli Lilly and Company

Completed

Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder

Depressive Disorder

United States
Eli Lilly and Company

Completed

Comparing 3 Schedules of Alimta Plus Gemzar

Neoplasms | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States
Eli Lilly and Company

Completed

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Breast Neoplasms

United States
Eli Lilly and Company

Completed

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Breast Neoplasms

United States, Argentina, Chile, India, Mexico
Eli Lilly and Company

Completed

A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

Colorectal Cancer

United States
Eli Lilly and Company

Completed

Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.

Colorectal Cancer

United States, Germany
Eli Lilly and Company

Completed

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

Bipolar Disorder

United States
Eli Lilly and Company

Completed

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

Acute Lung Injury | Respiratory Distress Syndrome, Adult

United States, Belgium, Spain, Canada, Australia, New Zealand
Eli Lilly and Company

Completed

Pharmacokinetic Characterization of Intramuscular Olanzapine Depot

Schizophrenia | Schizoaffective Disorder

Australia, Belgium, Brazil, Croatia, Czech Republic, Mexico, Slovakia, Spain
Eli Lilly and Company

Completed

Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression

Major Depressive Disorder

United States

Search clinical trials for: Lilly

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations